GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Akero Therapeutics
Akero Therapeutics is a biotech company developing drugs for the treatment of nonalcoholic steatohepatitis (NASH). Its stock price, like that of its competitors in this field, is driven by clinical trial results and hopes of developing the first approved drug for this vast market.
Share prices of companies in the market segment - Pharma metabolism
Akero Therapeutics is a biotechnology company focused on developing drugs to treat metabolic diseases, particularly NASH. We classify it as part of the pharmaceuticals (metabolism) sector, and the chart below reflects the general trends and sentiment in this area of biotechnology.
Broad Market Index - GURU.Markets
Akero Therapeutics is a biopharmaceutical company developing drugs to treat nonalcoholic steatohepatitis (NASH), a serious liver disease. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how Akero shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
AKRO - Daily change in the company's share price Akero Therapeutics
For Akero Therapeutics, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about clinical trials of its drugs. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Akero Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with AKRO's performance, which hinges on the results of clinical trials of its liver disease drugs, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Akero Therapeutics is a biopharmaceutical company developing drugs for the treatment of nonalcoholic steatohepatitis (NASH). This is a highly competitive and risky field. The chart below shows the segment's volatility, helping to assess how typical Akero's performance is for this niche.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Akero Therapeutics
Akero is a biotech company developing drugs to treat liver diseases. Its shares move in sync with news about clinical trials. This high, event-driven volatility feeds into the overall market flow.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Akero Therapeutics, Inc. is a clinical-stage biotech developing drugs for the treatment of metabolic steatohepatitis (MASH). Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this vast but complex area of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Akero Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the key events are data releases, not macroeconomic statistics.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Akero Therapeutics
Akero, a biopharmaceutical company, is a speculative company. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of its clinical trials for its metabolic steatohepatitis (MASH) drug, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Akero Therapeutics is a clinical-stage biotech company developing drugs for metabolic diseases, specifically non-alcoholic steatohepatitis (NASH). Its valuation is dependent on the success of its research. The chart below shows the overall dynamics of the biotech sector, known for its high volatility and potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Akero Therapeutics is a biotech company developing a breakthrough drug for the treatment of metabolic steatohepatitis (MASH). Its shares move in sync with clinical trial news. The chart below shows overall market sentiment, but Akero prioritizes its own scientific breakthroughs.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Akero Therapeutics
Akero Therapeutics, a biotech company developing a treatment for metabolic liver disease (NASH), is a hot topic among investors. Its weekly stock price is almost entirely driven by news about clinical trials, creating high volatility and a disconnect from overall market trends.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Biotech companies working on the treatment of metabolic liver disease (NASH), like Akero, are riding the wave of general news and expectations in this hot field. The chart below shows this general pulse, allowing one to assess how promising the market perceives Akero's technology compared to its numerous competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Akero Therapeutics is a biotech company developing a drug for the treatment of nonalcoholic steatohepatitis (NASH). This represents a huge potential market. The chart shows how news about clinical trials can cause sharp spikes and drops completely unrelated to the overall market.
Market capitalization of the company, segment and market as a whole
AKRO - Market capitalization of the company Akero Therapeutics
Akero Therapeutics' market capitalization chart is a financial expression of hope for a cure for nonalcoholic steatohepatitis (NASH). Its sharp ups and downs are a direct reaction from investors to the clinical trial results. The scale of its value, even without revenue, demonstrates the enormous potential market for an effective treatment for this disease.
AKRO - Share of the company's market capitalization Akero Therapeutics within the market segment - Pharma metabolism
Akero Therapeutics is a biotech company seeking to capture a share of the huge potential market for the treatment of metabolic steatohepatitis (MASH). Its market cap is based on promising clinical trial results for its lead drug.
Market capitalization of the market segment - Pharma metabolism
This chart shows the total value of the entire biotech sector focused on treating metabolic diseases like nonalcoholic steatohepatitis (NASH). For Akero Therapeutics, which is developing one of the leading drugs in this field, this line illustrates the scale of the obesity epidemic and related liver diseases, as well as the enormous potential reward.
Market capitalization of all companies included in a broad market index - GURU.Markets
Akero Therapeutics develops drugs to treat metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). Its capitalization represents hope for a solution to one of the "epidemics" of modern lifestyles. It represents a significant portion of the global fight against the consequences of obesity.
Book value capitalization of the company, segment and market as a whole
AKRO - Book value capitalization of the company Akero Therapeutics
Akero Therapeutics fights metabolic diseases, and its book value represents its scientific capital. It reflects its financial reserves for conducting expensive clinical trials, as well as the value of its intellectual property. How has this foundation changed over the course of development? The chart below illustrates this story.
AKRO - Share of the company's book capitalization Akero Therapeutics within the market segment - Pharma metabolism
Akero Therapeutics fights liver diseases, and its cutting-edge developments require a modern infrastructure. This includes in-house laboratories and investments in manufacturing facilities for the production of complex biologics. The chart shows the company's share of the physical infrastructure required to develop next-generation therapies.
Market segment balance sheet capitalization - Pharma metabolism
Akero Therapeutics develops drugs for the treatment of liver diseases. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Akero is an R&D company; its capital comes not from factories, but from intellectual property and clinical trial data.
Book value of all companies included in the broad market index - GURU.Markets
Akero Therapeutics fights liver diseases, and its assets are scientific and financial capital. The company's book value is derived from its research centers and funds allocated for large-scale clinical trials. The chart shows the material base that forms the foundation for the development of breakthrough therapies.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Akero Therapeutics
Akero Therapeutics' balance sheet is funded by research. But the market sees a potential blockbuster for liver disease (NASH). The chart shows a huge "hope factor," reflecting investors' faith in the success of its lead drug, valuing it several times higher than all current assets.
Market to book capitalization ratio in a market segment - Pharma metabolism
Akero Therapeutics is a biotech company developing drugs to treat serious metabolic diseases such as NASH (non-alcoholic steatohepatitis). Its valuation is based on the potential of its lead candidate. The chart demonstrates the investors' enormous confidence in the potential blockbuster.
Market to book capitalization ratio for the market as a whole
Akero Therapeutics develops drugs to treat nonalcoholic steatohepatitis (NASH), a serious liver disease associated with obesity. The company's assets are its research and development. This chart shows the overall market valuation, but how do investors value a biotech company aimed at treating a "disease of civilization" that affects millions of people?
Debts of the company, segment and market as a whole
AKRO - Company debts Akero Therapeutics
Akero Therapeutics is a biotech company focused on developing a treatment for a serious liver disease. Like its peers in the sector, debt is a potential tool for funding critical, late-stage clinical trials. It's a high-risk financial bet on the drug's future success.
Market segment debts - Pharma metabolism
Akero Therapeutics is a biotech company developing cutting-edge drugs for the treatment of metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). This represents a huge potential market, but research is very expensive. This chart shows how the company funds its ambitious clinical programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Akero Therapeutics
Akero Therapeutics is a biotech company developing drugs to treat serious metabolic diseases such as nonalcoholic steatohepatitis (NASH). This chart shows its financial position at the clinical trial stage. The absence of significant debt suggests that its development is financed through equity capital.
Market segment debt to market segment book capitalization - Pharma metabolism
Developing drugs to treat metabolic diseases, like Akero's, is a promising but highly capital-intensive field. This chart shows how the biotech sector as a whole funds its research. It allows one to assess how Akero Therapeutics' financial model relies on external capital for clinical trials compared to the industry.
Debt to book value of all companies in the market
This chart reflects the average "credit appetite" of the entire economy. Akero Therapeutics, a biotech company with no revenue, survives on investments in research. A comparison with the overall market, comprised of profitable businesses, clearly demonstrates the unique nature of its financial model, based on faith in a future breakthrough rather than current performance.
P/E of the company, segment and market as a whole
P/E - Akero Therapeutics
This chart for Akero Therapeutics, a biopharmaceutical company developing treatments for metabolic liver diseases, illustrates high expectations. Like many development-stage biotechs, its value is based not on profits, but on faith in the enormous potential of its lead drug candidate, which is targeting a multi-billion-dollar market.
P/E of the market segment - Pharma metabolism
Akero's focus on metabolic disease treatments represents a huge potential market. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Akero is valued not based on current profits, but rather on the potential blockbuster success of its steatohepatitis (NASH) treatment.
P/E of the market as a whole
Akero Therapeutics is a biotech company developing drugs to treat serious metabolic diseases, specifically nonalcoholic steatohepatitis (NASH), which affects the liver. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether AKRO's high valuation is based on the enormous potential of the NASH market or is driven by overall sentiment in the sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Akero Therapeutics
Akero Therapeutics is a biotech company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH), a serious liver disease. This chart reflects investor expectations for a potential breakthrough in the treatment of this common disease. Its momentum is a bet on the success of clinical trials and the commercialization of a first-in-class drug.
%20P%2FE%20Akero%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Akero-Therapeutics&v=1772693517470 "Chart of the company's future (projected) P/E Akero Therapeutics")
Future (projected) P/E of the market segment - Pharma metabolism
Akero Therapeutics is a biotech company developing drugs to treat serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). This chart plots its future profitability expectations against the broader industry, allowing one to assess how highly the market values the potential of its lead candidate.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772693517471 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Akero Therapeutics is a biotech company developing cutting-edge treatments for nonalcoholic steatohepatitis (NASH), a serious liver disease. Its valuation is a bet on success in one of the most challenging areas of medicine. Akero's valuation is largely independent of overall market expectations, but is driven by clinical trial data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772693517472 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Akero Therapeutics
Akero Therapeutics is a biotech company developing drugs to treat nonalcoholic steatohepatitis (NASH), a serious liver disease. Its financial picture reflects the costs of expensive clinical trials. This chart shows the investment in developing a drug that, if successful, could become a blockbuster in a multi-billion dollar market.
Profit of companies in the market segment - Pharma metabolism
Akero Therapeutics is a biotech company developing a breakthrough drug for the treatment of nonalcoholic steatohepatitis (NASH), a serious liver disease. This represents a huge potential market. This chart reflects the overall dynamics of the metabolic disease sector, where a successful treatment for a common condition could become a multibillion-dollar blockbuster.
Overall market profit
Akero Therapeutics is a biotech company developing drugs to treat metabolic liver diseases. Its shares are riding on anticipation of clinical trials. But the overall backdrop provided by this chart is important. A healthy economy and growing markets provide a more favorable environment for funding biotech innovations.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Akero Therapeutics
Akero Therapeutics is a biotech company developing a breakthrough drug for the treatment of nonalcoholic steatohepatitis (NASH), a serious liver disease. This represents a huge potential market. This chart shows analysts' assessments of the likelihood of clinical trial success and the future commercial potential of the company's drug.
%20profit%20of%20the%20company%20Akero%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Akero-Therapeutics&v=1772693517478 "Graph of future (projected) profit of the company Akero Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Akero Therapeutics is a biotech company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH), a serious liver disease. Its lead candidate could be a breakthrough in the treatment of this common condition. This chart shows revenue projections for the biotech sector, providing context for assessing Akero's potential to address one of the most pressing healthcare challenges.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772693517479 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Akero Therapeutics is a biotechnology company developing drugs to treat metabolic diseases. Like most companies in this sector, its value and future depend on the success of clinical trials. The macroeconomic metrics reflected in this market earnings forecast do not impact Akero's core scientific and regulatory processes.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772693517480 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Akero Therapeutics
Akero Therapeutics is a biotech company developing drugs to treat metabolic diseases. This chart is a look into the future. It correlates its market capitalization with modest current revenues, reflecting market expectations for the success of its lead drug candidate.
P/S market segment - Pharma metabolism
Akero Therapeutics is a biotech company developing drugs to treat nonalcoholic steatohepatitis (NASH), a serious liver disease. This chart shows the average revenue estimate in the biotech sector. It helps us understand the premium investors are pricing in for Akero's potential blockbuster, which targets the huge and unmet market for NASH treatments.
P/S of the market as a whole
Akero Therapeutics is developing cutting-edge drugs for the treatment of non-alcoholic steatohepatitis (NASH), a serious liver disease that is becoming increasingly common. Their success depends on the results of clinical trials. This chart provides a general revenue benchmark against which to judge the enormous expectations investors have for AKRO.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Akero Therapeutics
Akero Therapeutics is a biotechnology company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH), a serious liver disease. This chart reflects the company's high investor expectations for future sales. This valuation is based on the huge potential market for effective NASH treatments and promising clinical trial results.
%20P%2FS%20Akero%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Akero-Therapeutics&v=1772693517487 "The graph of the company's future (projected) P/S Akero Therapeutics")
Future (projected) P/S of the market segment - Pharma metabolism
Akero Therapeutics is a biopharmaceutical company developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). This represents a huge potential market. This chart compares the market's high expectations for its lead drug with those for the competitive biotech sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772693517492 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Akero Therapeutics is a biotech company developing drugs to treat serious metabolic diseases such as non-alcoholic steatohepatitis (NASH). This chart, reflecting investors' risk appetite, influences its funding. Market optimism allows companies like Akero to more easily raise the significant funds needed to conduct costly clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772693517492 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Akero Therapeutics
Akero Therapeutics is a biotech company developing drugs to treat nonalcoholic steatohepatitis (NASH), a serious liver disease. This chart reflects its financial flows, primarily from partnerships and funding. It does not represent commercial sales, but rather investments in developing a potentially breakthrough treatment for millions of patients.
Sales of companies in the market segment - Pharma metabolism
Akero Therapeutics is a biotechnology company focused on developing drugs for the treatment of serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Its activities are segmented by drug development programs. This chart depicts the financial flows associated with its lead candidate, showing its clinical and commercial progress.
Overall market sales
Akero Therapeutics is a biotech company developing drugs for the treatment of nonalcoholic steatohepatitis (NASH), a serious liver disease. Its success depends solely on the results of clinical trials. The company is working to address one of the most common and complex diseases of our time, and its potential breakthrough could change the lives of millions.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Akero Therapeutics
Akero Therapeutics is a biotechnology company developing drugs for the treatment of serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). The sales forecast is a market assessment of the potential of its lead drug to become an effective treatment for this common liver disease.
%20sales%20of%20the%20company%20Akero%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Akero-Therapeutics&v=1772693517496 "Schedule of future (projected) sales of the company Akero Therapeutics")
Future (projected) sales of companies in the market segment - Pharma metabolism
Akero Therapeutics is a biotech company developing drugs to treat serious metabolic diseases such as nonalcoholic steatohepatitis (NASH). This chart shows revenue expectations for the entire pharmaceutical sector. It reflects analysts' views on the potential of the massive NASH market and the prospects for new treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772693517496 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Akero Therapeutics, a biotech developing treatments for metabolic liver diseases, is dependent on the investment climate in the sector. This chart of overall sales forecasts reflects the overall economic climate, which influences investor risk appetite and funding for innovative developments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772693517498 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Akero Therapeutics
Akero Therapeutics is a clinical-stage biotechnology company focused on developing drugs to treat serious metabolic diseases such as nonalcoholic steatohepatitis (NASH). This chart reflects its trajectory, with significant investments in R&D laying the foundation for potential future profitability.
Market segment marginality - Pharma metabolism
Akero Therapeutics is a biotech company developing a drug for the treatment of nonalcoholic steatohepatitis (NASH), a serious liver disease. It represents a huge market with an unmet need. This graph provides an idea of the potential operational effectiveness of their lead drug if it successfully completes clinical trials and reaches the market.
Market marginality as a whole
Akero Therapeutics is a biotech company developing drugs to treat serious metabolic diseases, such as nonalcoholic steatohepatitis (NASH). Its value is based on the potential of its future drugs. This chart shows the profitability of mature businesses, whereas AKRO's success depends on clinical trial results and a huge potential market.
Employees in the company, segment and market as a whole
Number of employees in the company Akero Therapeutics
Akero Therapeutics is a biotech company developing drugs to treat serious metabolic diseases such as steatohepatitis (NASH). This chart shows the growth of its research team. This increase in intellectual capital is an indicator of progress in clinical trials.
Share of the company's employees Akero Therapeutics within the market segment - Pharma metabolism
Akero Therapeutics develops cutting-edge treatments for metabolic diseases such as non-alcoholic steatohepatitis (NASH). Clinical trials in this area are complex and require a large team. This chart shows the company's human capital contribution to the fight against one of the most common diseases of our time.
Number of employees in the market segment - Pharma metabolism
Akero Therapeutics is a biotech company developing drugs to treat serious metabolic diseases such as nonalcoholic steatohepatitis (NASH). This chart reflects employment in the pharmaceutical industry. The growing number of scientists working in the field of metabolic disorders highlights the enormous unmet need to treat these conditions.
Number of employees in the market as a whole
Akero Therapeutics is a biotech company developing treatments for liver diseases. While its operations are driven by scientific advances, a strong economy, symbolized by this chart, provides access to investment capital and ensures that the healthcare system can afford innovative drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Akero Therapeutics (AKRO)
Akero Therapeutics is a biotech company developing drugs to treat serious metabolic diseases. Its staff is small, but consists of leading scientists. The astronomically high market capitalization per employee, reflected in this chart, reflects the market's bet on the intellectual property and potential of its drug candidates.
%20of%20the%20company%20Akero%20Therapeutics%20(AKRO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Akero-Therapeutics-AKRO&v=1772693517531 "Chart of market capitalization per employee (in thousands of dollars) of the company Akero Therapeutics (AKRO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Akero Therapeutics (AKRO) is a clinical-stage biotech working on NASH (liver disease), the "holy grail" of pharma. Its value is pure R&D. This chart shows the (speculative) market value the market assigns to each elite scientist.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772693517534 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Akero Therapeutics is a biotech company developing drugs to treat serious metabolic diseases such as non-alcoholic steatohepatitis (NASH). Its value depends almost entirely on the success of clinical trials. The chart illustrates the enormous potential value the market sees in the work of each scientist.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772693517543 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Akero Therapeutics (AKRO)
Akero Therapeutics is a clinical-stage biotech company specializing in the treatment of serious metabolic diseases, specifically non-alcoholic steatohepatitis (NASH). This graph, likely negative, shows R&D intensity; how much capital the company is investing in each scientist to develop a potential blockbuster treatment for fatty liver disease.
%20Chart%20Akero%20Therapeutics%20(AKRO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Akero-Therapeutics-AKRO&v=1772693517549 "Company Profit Per Employee (in thousands of dollars) Chart Akero Therapeutics (AKRO)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Akero Therapeutics (AKRO) is an R&D company developing a drug (Efruxifermin) for the treatment of fatty liver disease (MASH/NASH). This chart shows the benchmark for "Pharma Metabolism" (Biotech). In this R&D sector, the benchmark is *negative*. Companies are burning billions on R&D. Profit per scientist is the goal of the future.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772693517550 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Akero Therapeutics (AKRO) is a biotech company developing drugs to treat metabolic diseases, particularly nonalcoholic steatohepatitis (NASH), a serious liver disease. This graph, showing average profit per employee, is important for biotech. It allows one to assess how much a sector where a handful of scientists can create a breakthrough drug outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772693517557 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Akero Therapeutics (AKRO)
Akero Therapeutics is a biotech company developing drugs for the treatment of metabolic liver diseases. While in clinical trials, its revenue may be zero. This graph will eventually reveal whether the small team of scientists can commercialize their developments and achieve high productivity.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Akero-Therapeutics-AKRO&v=1772693517563 "Sales chart per company employee Akero Therapeutics (AKRO)")
Sales per employee in the market segment - Pharma metabolism
Akero Therapeutics is a biotech company developing drugs to treat serious metabolic diseases, specifically nonalcoholic steatohepatitis (NASH). This chart shows revenue per employee. For a company in the R&D stage, the comparison to the segment reflects the efficiency of resource management and the potential of their developments (e.g., through partner fees).
Sales per employee for the market as a whole
Akero Therapeutics is a clinical-stage biotech company specializing in the treatment of non-alcoholic steatohepatitis (NASH), a "fatty liver disease." This is one of the hottest areas in biotech. Like other companies at this stage (PCVX, ACLX), they likely have no commercial revenue yet. This graph will show $0 until approval or a major partnership.
Short shares by company, segment and market as a whole
Shares shorted by company Akero Therapeutics (AKRO)
Akero Therapeutics is a biotech company developing a drug to treat MASH (formerly NASH) – non-alcoholic steatohepatitis (fatty liver disease). This represents a huge potential market, a "holy grail" for pharmaceuticals. But many have already failed. This chart shows the number of skeptics who don't believe in the efficacy or safety of Akero.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Akero-Therapeutics-AKRO&v=1772693517593 "Short Shares Chart for the Company Akero Therapeutics (AKRO)")
Shares shorted by market segment - Pharma metabolism
Akero Therapeutics (AKRO) is a biotech developing drugs to treat NASH (non-alcoholic steatohepatitis), a serious liver disease associated with obesity. This chart shows the betting against the biotech sector working on NASH. This is a "graveyard" for many drugs, and investors are shorting the sector, doubting the success of clinical trials.
Shares shorted by the overall market
Akero (AKRO) is a clinical-stage biotech (liver disease). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives AKRO of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Akero Therapeutics (AKRO)
Akero Therapeutics is a clinical-stage biotech focused on MASH (steatohepatitis). Shares are extremely sensitive to trial news. This chart for AKRO can soar above 70 on positive R&D data. A zone below 30 often reflects research setbacks or investor concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Akero-Therapeutics-AKRO&v=1772693517602 "RSI 14 indicator chart for the company's stock Akero Therapeutics (AKRO)")
RSI 14 Market Segment - Pharma metabolism
Akero (AKRO) is a biotech company, a leader in the hot race to develop a cure for MASH (non-alcoholic steatohepatitis). The RSI_14_Seg for "Pharma Metabolism" (biotech) reflects the overall sentiment. It helps us understand whether AKRO's volatility is a reaction to their trials or general hype in the sector.
RSI 14 for the overall market
Akero Therapeutics (AKRO) is a biotech company working on drugs for metabolic diseases (NASH). Like the entire sector, it relies on investors' money. This chart shows whether the funding window is open. Euphoria means easy money for R&D. Panic means running out of funds halfway through drug development.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AKRO (Akero Therapeutics)
Akero Therapeutics is a biotech company focused on the treatment of nonalcoholic steatohepatitis (NASH), a serious liver disease. Their lead candidate is efruxifermin (EFX). This chart shows the average analyst estimate, which represents their collective bet on the success of EFX's clinical trials and its potential in the vast but complex NASH market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AKRO-Akero-Therapeutics&v=1772693517611 "A chart showing analyst consensus forecasts for the expected stock price. AKRO (Akero Therapeutics)")
The difference between the consensus estimate and the actual stock price AKRO (Akero Therapeutics)
Akero Therapeutics is a biotech focused on developing therapies for MASH (non-alcoholic steatohepatitis), a silent epidemic of fatty liver disease. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in the success of its R&D pipeline (Efruxifermin) in this massive market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AKRO-Akero-Therapeutics&v=1772693517612 "A chart showing the difference between the consensus forecast and the actual stock price. AKRO (Akero Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Akero Therapeutics is a clinical-stage biotech focused on developing drugs for the treatment of MASH (formerly NASH) – non-alcoholic steatohepatitis (fatty liver disease). This chart shows analysts' overall expectations for the "metabolism" sector. It reflects whether experts believe breakthroughs are possible in this complex area of pharma.
Analysts' consensus forecast for the overall market share price
Akero Therapeutics is a biotech company at the forefront of the fight against MASH (formerly NASH) – non-alcoholic steatohepatitis, a fatty liver disease. This represents a huge potential market. This chart shows overall market sentiment. For Akero, as for any biotech, it's important how the overall risk appetite (analyst sentiment) influences funding for their developments. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Akero Therapeutics
Akero Therapeutics (AKRO) is a clinical-stage biotech focused on developing drugs for MASH (formerly NASH), a serious liver disease associated with obesity. This is the holy grail of pharma. This chart represents a high-risk R&D bet. Its valuation depends entirely on the clinical trial results of their lead drug, Efruxifermin.
AKIMA Market Segment Index - Pharma metabolism
Akero is a biotech (like Madrigal) that is racing to develop the first blockbuster treatment for MASH (NASH) – non-alcoholic fatty liver disease (a huge market). This summary metric evaluates R&D. The chart shows the average value for the segment. This is a benchmark: how does Akero's risky (MASH-like) R&D model differentiate it from the average pharma company?
The AKIM Index for the overall market
Akero is a biotech company, one of the leaders in the race to develop a drug for MASH (NASH) – fatty liver disease (a competitor to Madrigal). It's a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story, fueled by trial news, stacks up against the backdrop of overall economic trends.
